Clinical trial
Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and…
NCT00157040 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00157040 |
|---|---|
| Title | Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A |
| Official title | Recombinant Antihemophilic Factor (rAHF-PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Pharmacokinetics, Immunogenicity, Efficacy and Safety in Previously Treated Pediatric Patients With Hemophilia A |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Antihemophilic factor, recombinant, manufactured protein-free |
| Enrollment | 50 |
| Start date | Jun 7, 2002 |
| Primary completion | Jan 4, 2005 |
| Completion | Jan 4, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Apr 27, 2021 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: